Headlines about Laboratory Corporation of America Holdings (NYSE:LH) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Laboratory Corporation of America Holdings earned a news impact score of 0.13 on Accern’s scale. Accern also assigned news articles about the medical research company an impact score of 46.5251121800446 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the media stories that may have impacted Accern’s rankings:

LH has been the topic of several analyst reports. Canaccord Genuity reaffirmed a “buy” rating and issued a $180.00 target price (up from $175.00) on shares of Laboratory Corporation of America Holdings in a research report on Monday, September 11th. ValuEngine raised Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating in a research note on Wednesday, September 6th. Craig Hallum reissued a “buy” rating and issued a $179.00 price target (up previously from $157.00) on shares of Laboratory Corporation of America Holdings in a research note on Thursday, July 27th. Zacks Investment Research raised Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating and set a $173.00 price target for the company in a research note on Thursday, September 21st. Finally, SunTrust Banks, Inc. reissued a “buy” rating and issued a $190.00 price target on shares of Laboratory Corporation of America Holdings in a research note on Thursday, October 12th. Seven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $169.00.

Laboratory Corporation of America Holdings (NYSE:LH) last posted its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.38 by $0.08. The company had revenue of $2.60 billion during the quarter, compared to analysts’ expectations of $2.55 billion. Laboratory Corporation of America Holdings had a return on equity of 16.75% and a net margin of 7.40%. Laboratory Corporation of America Holdings’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.25 earnings per share.

In related news, Director Dwight Gary Gilliland sold 971 shares of the company’s stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $153.52, for a total transaction of $149,067.92. Following the sale, the director now owns 3,501 shares in the company, valued at $537,473.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider F Samuel Eberts III sold 31,500 shares of the company’s stock in a transaction dated Friday, August 25th. The stock was sold at an average price of $155.22, for a total value of $4,889,430.00. Following the sale, the insider now owns 31,894 shares in the company, valued at approximately $4,950,586.68. The disclosure for this sale can be found here. Insiders have sold 212,971 shares of company stock valued at $33,378,333 over the last ninety days. 0.90% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: This report was first published by Watch List News and is owned by of Watch List News. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.watchlistnews.com/laboratory-corporation-of-america-holdings-lh-earning-somewhat-positive-news-coverage-report-finds/1674802.html.

Laboratory Corporation of America Holdings Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Insider Buying and Selling by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with Analyst Ratings Network's FREE daily email newsletter.